Megestrol acetate for treatment of advanced carcinoma of the prostate

@article{Johnson1975MegestrolAF,
  title={Megestrol acetate for treatment of advanced carcinoma of the prostate},
  author={D. E. Johnson and K E Kaesler and Alberto G Ayala},
  journal={Journal of Surgical Oncology},
  year={1975},
  volume={7}
}
Thirteen men, ranging in age from 53 to 73 years and with previously untreated metastatic carcinoma of the prostate, received megestrol acetate (a synthetic progestin) in doses of 120 mg daily. A beneficial clinical response with a mean duration of 47 weeks was achieved in 12 patients (92%). When relapse developed in 8 patients, a secondary response was readily obtained by orchiectomy. The results suggest that a staged hormonal approach, using progestin therapy initially, may offer additional… 
View on Wiley
ncbi.nlm.nih.gov
36 Citations
Background Citations
1
Methods Citations
1

36 Citations

Citation Type

Citation Type

Megestrol acetate in relapsed carcinoma of prostate.
TLDR
It was concluded that megestrol acetate has a role as second-line hormonal therapy in the management of prostatic carcinoma.
Phase II study of megestrol acetate for metastatic carcinoma of the prostate.
TLDR
Megestrol acetate has only limited efficacy in patients previously treated for prostatic cancer by hormonal manipulation.
Treatment of stage D prostatic carcinoma with megestrol acetate
TLDR
Nine previously untreated patients with stage D prostatic carcinoma received megestrol acetate 40 mg orally three times daily, and three of five patients who had failed prior hormonal therapy remained objectively stable while receiving megestro acetate.
Medical castration using megestrol acetate and minidose estrogen.
TLDR
A high incidence of feminizing side effects, a higher than expected rate of cardiovascular complications, an unexpected need for cortisone replacement, and failure of patients with Stage D2 disease to obtain results better than those of standard therapy during the first year of observation suggest this regimen offers no advantage over other more conventional therapy.
Flutamide and other antiandrogens in the treatment of advanced prostatic carcinoma.
TLDR
Antiandrogens offer an alternative mode of therapy for previously untreated patients with advanced prostatic cancer but have produced no convincing benefits in hormonally refractory patients.
Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
TLDR
Despite a similar median progression-free actuarial rate, the combined treatment offered an improved survival time over orchiectomy alone and the combined therapy was well-tolerated by patients, and they noted a better relief of bone pain after six months.
Treatment of advanced cancer of prostate with megestrol acetate.
TLDR
Since megestrol appears to be effective therapy for previously untreated prostatic cancer and since it does not cause gynecoinastia, salt retention, or thromboembolism, it should be studied further as a possible first line drug in the treatment of Stage D prostaticcancer.
5 The role of endocrine therapy in prostatic cancer
TLDR
Current endocrine therapies offer symptomatic relief to prostatic cancer patients for an average period of 1–2 years following initiation of therapy, suggesting that disease progression is independent of androgens.
Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate.
TLDR
Since megestrol acetate plus minidose DES is equivalent to DES in achieving treatment responses in patients with carcinoma of the prostate, it is a preferable treatment because of its improved side-effect profile.
Treatment of prostatic cancer. Newer forms of androgen deprivation.
TLDR
Encouraging the initiation of androgen deprivation for patients with regional or distant metastases will improve the patient's course and attempts to provide a more complete androgen blockade hold the hope of delaying or preventing relapse, which usually occurs with continued androgens deprivation.
...
1
2
3
4
...

References

SHOWING 1-8 OF 8 REFERENCES
The use of progesterone in treatment of cancer of the prostate.
TLDR
A clinical evaluation of the effect of progesterone not only in patients in whom the disease has relapsed, but also in previously untreated cases.
Progestin therapy of breast cancer: comparison of agents.
  • B. Stoll
  • Medicine
    British medical journal
  • 1967
TLDR
It is suggested that the metabolism of different progestins might be investigated in breast cancer patients by the administration of radioactively tagged progestin derivatives.
An endocrine basis for endometrial carcinoma.
TLDR
The urine assays for LH showed that the patients with primary adenocarcinoma of the endometrium had elevated LH levels in all 31 cases and following bilateral oophorectomy the level of LH fell to normal in all the cases.
Probable mode of action of oral contraceptives.
TLDR
It is concluded that the mode of action of oral contraceptives is not completely understood and biochemical rather than morphological endometrial change may be most important.
Receptor Proteins for Androgens ON THE ROLE OF SPECIFIC PROTEINS IN SELECTIVE RETENTION OF 17β-HYDROXY-5α-ANDROSTAN-3-ONE BY RAT VENTRAL PROSTATE IN VIVO AND IN VITRO
TLDR
The antagonistic action of antiandrogens strongly supports the contention that the binding of 5α-dihydrotestosterone by proteins described in this paper is germane to the stimulation of prostate growth and function by androgens.
Cyproterone acetate in the treatment of advanced carcinoma of the prostate.
Experience in the treatment of prostatic carcinoma with cyproterone acetate.
Mechanism of androgenic action: effect of specific intracellular inhibitors.